Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs TG Therapeutics Inc — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $72.14 (market cap $6.94B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Low Volatility ETF for 123 Days and TG Therapeutics Inc for 16 Days on average.
| SPLV | TGTX | |
|---|---|---|
Market Cap | $6.94B | $8.16B |
Volume | 1,663,703 | 1,735,121 |
52-Week High | $77.97 | $59.06 |
52-Week Low | $70.30 | $26.94 |
Typical Hold Time | 123 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV trades at $71.97, up 1.05% today, but faces bearish technical signals with moving averages indicating selling pressure. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 provide income support, while geopolitical tensions and market volatility highlight the fund's defensive positioning.
Outlook remains neutral with valuation concerns at 19.5x P/E. Key risks include sector concentration and macroeconomic headwinds, while opportunities lie in low-volatility appeal during market uncertainty. The ETF serves as a defensive play but faces growth-adjusted valuation challenges.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
